207 related articles for article (PubMed ID: 17786474)
1. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas.
Salas S; Bartoli C; Deville JL; Gaudart J; Fina F; Calisti A; Bollini G; Curvale G; Gentet JC; Duffaud F; Figarella-Branger D; Bouvier C
Virchows Arch; 2007 Dec; 451(6):999-1007. PubMed ID: 17786474
[TBL] [Abstract][Full Text] [Related]
2. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma.
Park HR; Jung WW; Bacchini P; Bertoni F; Kim YW; Park YK
Pathol Res Pract; 2006; 202(7):509-15. PubMed ID: 16677779
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma.
Mu Y; Zhang H; Che L; Li K
Med Oncol; 2014 Feb; 31(2):821. PubMed ID: 24352761
[TBL] [Abstract][Full Text] [Related]
4. Expression change of ezrin as a prognostic factor in primary osteosarcoma.
Wang YF; Shen JN; Xie XB; Wang J; Huang G
Med Oncol; 2011 Dec; 28 Suppl 1():S636-43. PubMed ID: 20859706
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
6. Ezrin expression predicts survival in stage IIB osteosarcomas.
Kim MS; Song WS; Cho WH; Lee SY; Jeon DG
Clin Orthop Relat Res; 2007 Jun; 459():229-36. PubMed ID: 17353802
[TBL] [Abstract][Full Text] [Related]
7. Ezrin and moesin expression in canine and feline osteosarcoma.
Hlavaty J; Wolfesberger B; Hauck M; Obermayer-Pietsch B; Fuchs-Baumgartinger A; Miller I; Walter I
Histol Histopathol; 2017 Aug; 32(8):805-816. PubMed ID: 27900754
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell.
Di Cristofano C; Leopizzi M; Miraglia A; Sardella B; Moretti V; Ferrara A; Petrozza V; Della Rocca C
Mod Pathol; 2010 Jul; 23(7):1012-20. PubMed ID: 20348881
[TBL] [Abstract][Full Text] [Related]
9. Immunoexpression of Ezrin and CD44 in patients with osteosarcoma.
Boldrini E; Peres SV; Morini S; de Camargo B
J Pediatr Hematol Oncol; 2010 Aug; 32(6):e213-7. PubMed ID: 20562647
[TBL] [Abstract][Full Text] [Related]
10. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC.
Ren L; Hong SH; Cassavaugh J; Osborne T; Chou AJ; Kim SY; Gorlick R; Hewitt SM; Khanna C
Oncogene; 2009 Feb; 28(6):792-802. PubMed ID: 19060919
[TBL] [Abstract][Full Text] [Related]
11. Role of ezrin in osteosarcoma metastasis.
Ren L; Khanna C
Adv Exp Med Biol; 2014; 804():181-201. PubMed ID: 24924175
[TBL] [Abstract][Full Text] [Related]
12. Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone.
Ueda T; Araki N; Mano M; Myoui A; Joyama S; Ishiguro S; Yamamura H; Takahashi K; Kudawara I; Yoshikawa H
J Clin Pathol; 2002 Nov; 55(11):853-8. PubMed ID: 12401825
[TBL] [Abstract][Full Text] [Related]
13. High level of ezrin mRNA expression in an osteosarcoma biopsy sample with lung metastasis.
Ogino W; Takeshima Y; Mori T; Yanai T; Hayakawa A; Akisue T; Kurosaka M; Matsuo M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):435-9. PubMed ID: 17609619
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Role of Ezrin and HER2/neu Expression in Osteosarcoma.
Abdou AG; Kandil M; Asaad NY; Dawoud MM; Shahin AA; Abd Eldayem AF
Appl Immunohistochem Mol Morphol; 2016; 24(5):355-63. PubMed ID: 26067138
[TBL] [Abstract][Full Text] [Related]
15. Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma.
Salas S; de Pinieux G; Gomez-Brouchet A; Larrousserie F; Leroy X; Aubert S; Decouvelaere AV; Giorgi R; Fernandez C; Bouvier C
Virchows Arch; 2009 Jan; 454(1):81-7. PubMed ID: 19050913
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Role of Ezrin Immunoexpression in Osteosarcoma: A Meta-Analysis of Published Data.
Li H; Min D; Zhao H; Wang Z; Qi W; Zheng S; Tang L; He A; Sun Y; Yao Y; Shen Z
PLoS One; 2013; 8(6):e64513. PubMed ID: 23805177
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults.
Lugowska I; Mierzejewska E; Lenarcik M; Klepacka T; Koch I; Michalak E; Szamotulska K
Tumour Biol; 2016 Sep; 37(9):12071-12078. PubMed ID: 27207343
[TBL] [Abstract][Full Text] [Related]
19. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin.
Zhu J; Feng Y; Ke Z; Yang Z; Zhou J; Huang X; Wang L
Am J Pathol; 2012 Jun; 180(6):2440-51. PubMed ID: 22525461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]